Cen Chen

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

O. O’Connor, X. An, Faming Zhang, 2023, Scientific Reports.

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models

X. An, Lingxin Xiong, Lei Zhang, 2024, Scientific reports.